Acyclovir will go to the United States, and the domestic market is very hot

With the arrival of spring, various viruses began to be active after the weather turned warm Herpes zoster virus is one of them At this time, the infection becomes very strong The elderly and people with low immunity belong to high-risk groups The virus is easily transmitted through the respiratory tract, which causes high incidence of herpes zoster On March 13, Shijiazhuang Yiling Pharmaceutical Co., Ltd issued the "announcement on the wholly-owned subsidiary's preparation products obtaining the US FDA approval number", and the brief application of acyclovir for new drugs declared by Yiling Wanzhou International Pharmaceutical Co., Ltd to the FDA has been approved, becoming another preparation drug listed in the US The lack of new antiherpesvirus drugs accounts for more than half of the main epidemic diseases According to IMS data, the global market for antiviral drugs reached US $37.5 billion in 2016 (excluding anti HIV) In recent years, with the lack of new antiherpesvirus drugs, the global market for antiherpesvirus drugs in 2016 was US $2.158 billion, accounting for only 5.75% of the antiviral market, down 7% year on year Herpes zoster occurs on the surface of the skin Its source is the related virus in the body, and the virus gradually invades the body of the patient, especially in the long-term hidden in the nerve 10% of the patients with herpes zoster will suffer from sequelae neuralgia In medicine, shingles are mainly targeted at drug treatment and vaccine prevention Zostavax, a herpes zoster vaccine developed by MSD, is the main foreign vaccine for the prevention of herpes zoster In 2016, the global sales volume of Zostavax reached 685 million US dollars At present, the domestic herpes zoster vaccine is still in the application, while the Zostavax of mosadong has not been listed in China Therefore, at present, the domestic treatment is mainly targeted with drugs In the past two years, the global R & D pipeline of antiviral drugs has continued to move forward, and many new drugs have emerged in the domestic antiviral market However, the market of broad-spectrum antiviral drugs and antiherpesvirus drugs is far less rapid than that of anti HCV, HIV and HBV Antiviral drugs sales fluctuation antiherpesvirus drugs are a kind of drugs which developed rapidly at the end of the 20th century They are growing rapidly in variety, quantity and amount of drug use, which objectively drives the improvement of the overall level of antiviral drugs The broad-spectrum antiviral nucleoside and nucleotide drugs included in the 2017 edition of the national medical insurance drug catalog include acyclovir, famciclovir, ganciclovir, valaciclovir and ribavirin, as well as other antiviral drugs, sodium phosphonate, which basically cover the common drugs of broad-spectrum antiviral and herpes virus In general, the domestic drugs for herpes zoster treatment have been synchronized with foreign drugs According to minenet data, in 2016, the market scale of antiviral drugs in public hospitals and retail pharmacies in key cities in China was RMB 2.424 billion and RMB 1.419 billion, respectively The amount of antiviral drugs in public hospitals in key cities increased by 11.88% year on year, while the sales volume of antiviral drugs in retail pharmacies decreased by 3.58% According to the statistics in the first three quarters of 2017, it is predicted that the amount of antiviral drugs used in public hospitals in key cities in 2017 will be 2.658 billion yuan, an increase of 9.68% over the previous year Under the situation of the spread of influenza virus, the sales volume of antiviral drugs in drugstores in key cities in China increased by 4.39%, reaching 1.428 billion yuan It is worth mentioning that the market of broad-spectrum antiviral and antiherpesvirus drugs is also growing at the same time when the market of antiviral drugs is mutated The retail terminal of anti herpesvirus drugs should not be underestimated According to the data of mienei.com, in 2016, the amount of anti herpesvirus drugs used in public hospitals in key cities in China was 164 million yuan, and in 2017, it was predicted to be 168 million yuan, with a growth rate of only 2.5% compared with the previous year It is worth noting that in 2016, the retail market scale of anti herpesvirus drugs in drugstores in key cities was 150 million yuan, an increase of 14.4% over the previous year Some patients with genital herpes have a high proportion of self medication, and the retail terminal of pharmacies has become a hot spot, so the retail sales of anti herpesvirus drugs in pharmacies are significantly better than that in hospitals In 2017, the competition pattern of six anti herpesvirus drugs in public hospitals in key cities in China was: 41.41% for adenosine, 29.07% for valaciclovir, 12.14% for acyclovir, 9.85% for panciclovir, 6.38% for penciclovir and 1.15% for brovudine At the beginning of the new century, the new drugs, such as famciclovir and penciclovir, have not surpassed acyclovir Acyclovir is a synthetic purine nucleoside analogue It is a drug for the treatment of herpes simplex virus, such as keratitis, skin and mucous membrane infection, genital herpes, herpesvirus encephalitis, herpes zoster and varicella in immunodeficient patients It has significant curative effect and rich dosage forms Acyclovir can effectively inhibit the reactivation of the virus and the newly acquired viral diseases Oral acyclovir can reduce the incidence rate and mortality of immunodeficiency virus diseases, and can also be used for preventing infection before and after operation Acyclovir can prevent and cure acute varicella and herpes zoster It has a certain market base at home and abroad According to IMS data, in 2016, the sales volume of acyclovir tablets in the U.S market reached 21.73 million US dollars The main manufacturers of acyclovir tablets in the U.S include camper, Teva and zydus The number of domestic acyclovir hospital terminals increased by 89% According to the data of mienei network, there are more acyclovir manufacturers in China, with 290 production approvals In 2016, the amount of acyclovir used in public hospitals in key cities in China was 10.76 million yuan, an increase of 46.20% over the previous year According to the data forecast for the first three quarters of 2017, the amount of acyclovir used in public hospitals in key cities in 2017 was 20.39 million yuan, an increase of 89.50% over the previous year According to the data of mienei.com, in 2016, the sales volume of acyclovir retail market of drugstores in key cities in China was 45.92 million yuan, an increase of 27.49% over the previous year It is predicted that the scale of acyclovir retail market of drugstores in key cities in China will be nearly 60 million yuan in 2017, an increase of 29.85% over the previous year It can be seen that the sales of antiherpesvirus drugs in drugstores is significantly better than that in the hospital market, which is the same as that of anti ed drugs The top 5 brands of acyclovir in the drugstore market are: Sinopharm holding Xingsha Pharmaceutical (Xiamen) accounts for 13.21%, Hubei Sihuan pharmaceutical accounts for 13.07%, Heilongjiang Tianchen pharmaceutical accounts for 12.61%, Shenzhen Haiwang pharmaceutical accounts for 9.32%, Fujian Pacific pharmaceutical accounts for 6.37%, and others account for 45.42% The market concentration is not high.